The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...
Inhibidores de las Cinasas Janus/uso terapéutico,
COVID-19/tratamiento farmacológico,
Antivirales/uso terapéutico,
Ivermectina/uso terapéutico,
Hidroxicloroquina/uso terapéutico,
Plasma/inmunología,
Fluvoxamina/uso terapéutico,
Colchicina/uso terapéutico,
Inmunización Pasiva,
Receptores de Interleucina-6/uso terapéutico,
Lopinavir/uso terapéutico,
Corticoesteroides/uso terapéutico
The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is impor...
COVID-19/complicaciones,
COVID-19/diagnóstico,
Máscaras,
Salud Global,
Hospitalización,
Respiración Artificial,
Choque Séptico,
Lactancia Materna,
Embarazo,
Síndrome de Dificultad Respiratoria/etiología,
Neumonía Viral/etiología,
Cuidados Paliativos,
Rehabilitación,
Manejo de Atención al Paciente/organización & administración
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for persons aged 12-17 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRADE...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6–11 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRA...
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CD...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), in late 2019 has led to a global pandemic with dramatic societal and economic impact on individual persons and communities. In the United States, more than 89 million cases and more than 1 million COVID-19-associated ...
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use ...
COVID-19/tratamiento farmacológico,
Corticoesteroides/uso terapéutico,
Antivirales/uso terapéutico,
COVID-19/complicaciones,
Embolia Pulmonar/complicaciones,
Pulmón/patología,
Anticoagulantes/uso terapéutico,
Dabigatrán/uso terapéutico,
Heparina/uso terapéutico,
4-Hidroxicumarinas/uso terapéutico,
Aspirina/uso terapéutico
This guideline covers vitamin D use in the context of COVID‑19. It is for adults, young people and children in hospitals and community settings. Vitamin D is important for bone and muscle health. It may also have a role in the body's immune response to respiratory viruses. On 14 July 2022, we removed t...
